Bioequivalence study of 2 orodispersible formulations of ondansetron 8 mg in healthy volunteers

M. Cánovas*, J. Rios, G. Domenech, J. Cebrecos, P. Pelagio, M. Canals, F. Polonio, F. Cabré

*Autor corresponent d’aquest treball

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

5 Cites (Scopus)

Resum

This study was designed to compare the rate and extent of absorption of 2 oral formulations of ondansetron (CAS 99614-02-5) 8 mg orodispersible tablets in healthy volunteers. 22 subjects were administered ondansetron orodispersible tablets of test and reference formulation in a single-dose, 2-period, 2-sequence, fasting, open-label, crossover and randomised study. Plasma concentrations were determined by LC/MS/MS. Log-transformed AUCs and C max values were tested for bioequivalence based on the ratios of the geometric means (test/reference). T max was analysed nonparametrically. The 90% confidence intervals of the geometric mean values for the test/reference ratios for AUC 0-t and C max were within the bioequivalence acceptance range of 80-125%. According to the European Guideline [1] it may be therefore concluded that test formulation of ondansetron 8 mg orodispersible tablet is bioequivalent to the reference formulation. © Georg Thieme Verlag KG · Stuttgart · New York.
Idioma originalAnglès
Pàgines (de-a)59-62
Nombre de pàgines4
RevistaArzneimittel-Forschung/Drug Research
Volum62
Número2
DOIs
Estat de la publicacióPublicada - 1 de febr. 2012

Fingerprint

Navegar pels temes de recerca de 'Bioequivalence study of 2 orodispersible formulations of ondansetron 8 mg in healthy volunteers'. Junts formen un fingerprint únic.

Com citar-ho